Aliskiren Hemifumarate

Aliskiren (INN) (trade names Tekturna, U.S.; Rasilez, U.K. and elsewhere) is the first in a class of drugs called direct renin inhibitor. Its current licensed indication is primary (previously essential) hypertension.

Systematic (IUPAC) name	(2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide
CAS number	173334-57-1
ATC code	C09XA02,C09XA52
PubChem	5493444
DrugBank
Formula:	C30H53N3O6
Molecular mass	551.758 g/mol
Assay/Purity	Typically NLT 98%

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.